<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734652</url>
  </required_header>
  <id_info>
    <org_study_id>CAPRISA 093</org_study_id>
    <secondary_id>1R01AI152142-01</secondary_id>
    <nct_id>NCT04734652</nct_id>
  </id_info>
  <brief_title>INSTI's For The Management of HIV-associated TB</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>A Phase 2b Study to Evaluate the Efficacy, Safety and PK of a Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate for Treatment of HIV-1 Infection in Patients With Drug-susceptible Tuberculosis on a Rifampicin-based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for the AIDS Programme of Research in South Africa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for the AIDS Programme of Research in South Africa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the antiretroviral activity of a fixed-drug, single&#xD;
      tablet, combination of Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir alafenamide 25mg&#xD;
      (Biktarvy®) dosed twice daily in HIV-1 infected, ART-naïve patients with TB co-infection&#xD;
      receiving a rifampicin-based tuberculosis (TB) treatment regimen. This study will assess the&#xD;
      activity of Bictegravir and dolutegravir-containing ART regimens in patients with&#xD;
      drug-susceptible TB through 48 weeks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: To characterize viral suppression rates (proportion of patients with&#xD;
      suppressed viral load) at week 24 in the BIC arm&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To characterize viral suppression rates at weeks 12, 24 and 48 in the standard of care&#xD;
      treatment (SOC) arm (currently, TDF 300mg/3TC 300mg/DTG 50mg) and at weeks 12 and 48 in the&#xD;
      BIC/FTC/TAF arm.&#xD;
&#xD;
      To compare the pharmacokinetics (PK) of BIC when given twice daily and co-administered with&#xD;
      Rifampicin during tuberculosis treatment vs when given alone after discontinuation of&#xD;
      Rifampicin&#xD;
&#xD;
      To assess the incidence of TB associated IRIS in each arm, through week 24.&#xD;
&#xD;
      To characterize the tolerability of treatment in each arm by assessing frequency of&#xD;
      clinician-initiated treatment interruptions or switches through week 48.&#xD;
&#xD;
      To assess frequency of ART drug resistance mutations in participants with detectable viral&#xD;
      load at study visit weeks 24 and 48.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 4, 2021</start_date>
  <completion_date type="Anticipated">October 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>80 participants for the Intervention Arm ART regimen which is a fixed-drug combination of a single tablet co-formulated regimen containing Bictegravir 50mg Emtricitabine 200mg and tenofovir alafenamide 25mg (BIC/FTC/TAF; Biktarvy®) that will be taken twice a day during rifampicin-containing TB treatment and 2 weeks after stopping TB treatment, thereafter the BIC/FTC/TAF single tablet co-formulation will be taken once daily.&#xD;
40 participants in the Control ARM: Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg (TLD- fixed-drug combination single tablet) plus Dolutegravir 50mg evening dose during TB treatment and for two weeks after completion of TB treatment, then TLD once daily thereafter- as per Standard of Care (SOC)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral suppression rate</measure>
    <time_frame>Week 24</time_frame>
    <description>Viral suppression rate (HIV-1 RNA &lt;50 copies/mL) at week 24 in the BIC arm (using the FDA snapshot algorithm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral suppression rates</measure>
    <time_frame>At weeks 12, 24 and 48</time_frame>
    <description>Viral suppression rates (HIV-1 RNA &lt;50 copies/mL) in the DTG arm and at 12 and 48 weeks in the BIC arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIC Drug concentrations (&quot;Area under the plasma concentration versus time curve (AUC)&quot;</measure>
    <time_frame>Week 4, 8 12, 24, 32 and 40</time_frame>
    <description>BIC drug levels (AUC) when given twice daily and co-administered with Rifampicin vs. during TB treatment vs when given alone after TB treatment completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIC Drug concentrations [Peak Plasma Concentration (Cmax)]</measure>
    <time_frame>Week 4, 8 12, 24, 32 and 40</time_frame>
    <description>BIC drug levels (Cmax) when given twice daily and co-administered with Rifampicin vs. during TB treatment vs when given alone after TB treatment completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIC Drug concentrations [Trough/Minimum Plasma Concentration Ctrough)</measure>
    <time_frame>Week 4, 8 12, 24, 32 and 40</time_frame>
    <description>BIC drug levels ( Ctrough) when given twice daily and co-administered with Rifampicin vs. during TB treatment vs when given alone after TB treatment completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of TB associated IRIS</measure>
    <time_frame>Through week 24</time_frame>
    <description>To assess the incidence of TB associated IRIS in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The tolerability of treatment in each arm</measure>
    <time_frame>Through week 48</time_frame>
    <description>To characterize the tolerability of treatment in each arm by assessing frequency of clinician-initiated treatment interruptions or switches through week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of ART drug resistance mutations</measure>
    <time_frame>study visit weeks 24 and 48.</time_frame>
    <description>To assess frequency of ART drug resistance mutations in participants with detectable viral load</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>BIC arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Intervention Arm ART regimen is a fixed-drug combination of a single tablet co-formulated regimen containing Bictegravir 50mg Emtricitabine 200mg and tenofovir alafenamide 25mg (BIC/FTC/TAF; Biktarvy®) that will be taken twice a day during rifampicin-containing TB treatment and 2 weeks after stopping TB treatment, thereafter the BIC/FTC/TAF single tablet co-formulation will be taken once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTG Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg (TLD- fixed-drug combination single tablet) plus Dolutegravir 50mg evening dose during TB treatment and for two weeks after completion of TB treatment, then TLD once daily thereafter- as per Standard of Care (SOC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Biktarvy®</intervention_name>
    <description>Biktarvy® is a fixed dose combination, single tablet containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) for oral administration.&#xD;
BIC is an integrase strand transfer inhibitor (INSTI). FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Each tablet contains 50 mg of BIC (equivalent to 52.5 mg of bictegravir sodium), 200 mg of FTC, and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose.</description>
    <arm_group_label>BIC arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TLD- fixed-drug combination single tablet</intervention_name>
    <description>Standard of care Dolutegravir-based regimen</description>
    <arm_group_label>DTG Arm</arm_group_label>
    <other_name>Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years of age with Karnofsky score ≥ 70&#xD;
&#xD;
          -  Confirmed rifampicin-susceptible tuberculosis (GeneXpert, Sputum smear and/or culture)&#xD;
&#xD;
          -  On first-line rifampicin-based tuberculosis treatment (not &gt; 8 weeks at the time of&#xD;
             enrolment)&#xD;
&#xD;
          -  Documented HIV-1 infection, ART-naïve&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2&#xD;
&#xD;
          -  Able and willing to provide written informed consent&#xD;
&#xD;
          -  Female patients agree to use both a barrier and a non-barrier form of contraception&#xD;
             during the study, starting at least 14 days prior to enrolment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding (or planned pregnancy within 12 months of study entry)&#xD;
&#xD;
          -  Prior use of antiretroviral drugs for pre-exposure prophylaxis (PrEP) or post-exposure&#xD;
             prophylaxis (PEP)&#xD;
&#xD;
          -  Hepatitis B surface antigen positive, Hepatitis B virus (HBV) infection, active&#xD;
             infections (other than HIV-1 infection) requiring systemic antibiotic or antifungal&#xD;
             therapy current or within 30 days prior to baseline&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) of &gt; 3 x upper limit of normal&#xD;
&#xD;
          -  Participants with a CD4+ cell count of &lt; 100 cells/ μl&#xD;
&#xD;
          -  Any verified Grade 4 laboratory abnormality, with the exception of, Grade 4&#xD;
             triglycerides. A single repeat test is allowed during the Screening period to verify a&#xD;
             result&#xD;
&#xD;
          -  Patients on metformin (&gt; 500mg, 12hourly)&#xD;
&#xD;
          -  Patients with an uncontrolled psychiatric co-morbidity. Patients who, in the&#xD;
             investigator's judgment, pose a significant suicidality risk. Recent history of&#xD;
             suicidal behavior and/or suicidal ideation may be considered as evidence of serious&#xD;
             suicide risk&#xD;
&#xD;
          -  Other condition or circumstance deemed by clinician/investigators to be detrimental to&#xD;
             patient safety or study conduct&#xD;
&#xD;
          -  Unwilling to be part of the main pharmacokinetic (PK) study and have PK blood draws&#xD;
             done (NB there is a semi intensive PK substudy which is optional)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anushka Naidoo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kelly Dooley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kogieleum Naidoo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre for the AIDS Programme of Research in South Africa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Smita Maharaj</last_name>
    <phone>+27316550510</phone>
    <phone_ext>5510</phone_ext>
    <email>Smita.Maharaj@caprisa.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheryl Baxter, PhD</last_name>
    <phone>+27312604559</phone>
    <phone_ext>4559</phone_ext>
    <email>cheryl.baxter@caprisa.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CAPRISA Springfield Clinical Research Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Anushka Naidoo, PhD</last_name>
      <phone>+27316550553</phone>
      <email>anushka.naidoo@caprisa.org</email>
    </contact>
    <contact_backup>
      <last_name>Kogieleum Naidoo, Phd</last_name>
      <phone>+27312604687</phone>
      <phone_ext>4687</phone_ext>
      <email>kogie.naidoo@caprisa.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for the AIDS Programme of Research in South Africa</investigator_affiliation>
    <investigator_full_name>Anushka Naidoo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Biktarvy® is a fixed dose combination</keyword>
  <keyword>TLD- fixed-drug combination single tablet</keyword>
  <keyword>Dolutegravir 50mg</keyword>
  <keyword>HIV/AIDS</keyword>
  <keyword>Tuberculosis, Pulmonary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data generated under this project will be shared in accordance with CAPRISA, and NIH-SAMRC policies, including the NIH Data Sharing Policy. Research data that documents, supports, and validates research findings will be made available after the main findings from the final research data set have been accepted for publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Not longer than 12 months after first publication of results. In accordance with WHO stipulations, summary results or a link to summary results will be reported within the trial registration record within 12 months of the study completion date.</ipd_time_frame>
    <ipd_access_criteria>Access to databases and associated software tools generated under the project will be available for educational, research, and non-profit purposes from bona-fide researchers and/or research organisations.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT04734652/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

